 |
|
Obesity and Survival Among Patients With Pancreatic Cancer—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Goldstein and colleagues raise the question of whether use of statins or antidiabetic medications confounds the relationship between body mass index and pancreatic cancer survival. To answer this question, we first conducted survival analysis in 450 nondiabetic patients identified from the 609 patients who were involved in the survival analysis in our original study. We found the median survival time for normal weight, overweight, and obese patients was 18.5, 16.1, and 13.2 months, respectively (log-rank P = .28 [normal weight vs overweight] and .002 [normal weight vs obese]). Compared with normal weight patients, the hazard ratio (HR) was 1.31 (95% confidence interval [CI], 0.92-1.85) for overweight patients and 1.99 (95% CI, 1.34-1.48) for obese patients after adjusting for clinical predictors.
We next examined the association between diabetes and pancreatic cancer survival in the same study population and found that patients with diabetes had reduced overall survival compared with . . . [Full Text of this Article]
Donghui Li, PhD
dli@mdanderson.org
Manal M. Hassan, MD, PhD;
James L. Abbruzzese, MD
Department of Gastrointestinal Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Obesity and Survival Among Patients With Pancreatic Cancer
Mark R. Goldstein, Luca Mascitelli, and Francesca Pezzetta
JAMA. 2009;302(16):1752.
EXTRACT
| FULL TEXT
|
